[5] She is co-chair of the Calcium pyrophosphate deposition (CPPD) Working Group, (OMERACT),[6][7] and was part of the Core Leadership Team for 2020 American College of Rheumatology Guideline for the Management of Gout.
[8] Dalbeth is an Associate Investigator at the Maurice Wilkins Centre for Molecular Biodiscovery,[9] and a Consultant for Auckland District Health Board Rheumatology Services.
"[13] A paper published in 2021 summarising research that Dalbeth had been involved in, concluded that there was the existence of population-amplified genetic variants conferring risk of gout in Polynesian populations.
"[15] Dalbeth was elected a Fellow of the Royal Society of New Zealand in 2019, an "honour that recognises distinction in research, scholarship or the advancement of knowledge at the highest international standards.
Professor John Fraser, the Dean of the Faculty of Medical and Health Science said "[that] Nicola's research has contributed to dispelling the many myths about gout and her findings have been instrumental in improving the treatments available for patients with this debilitating disease.